Gene · 4070
Papers3,230
Newest first. Swiss-Prot's references are curated; PubTator's text mining finds papers that name the gene, not always ones about it.
941 to 960 of 3,230
Download this page as JSON| Title | Journal | Year | PMID | Found by | Source |
|---|---|---|---|---|---|
| Extracellular Vesicles in Triple-Negative Breast Cancer: Immune Regulation, Biomarkers, and Immunotherapeutic Potential. | Cancers (Basel) | 2023 | 37835573 | PubTator, text mining | PubMed |
| Insulin Receptor Isoforms and Insulin Growth Factor-like Receptors: Implications in Cell Signaling, Carcinogenesis, and Chemoresistance. | Int J Mol Sci | 2023 | 37834454 | PubTator, text mining | PubMed |
| Progression after First-Line Cyclin-Dependent Kinase 4/6 Inhibitor Treatment: Analysis of Molecular Mechanisms and Clinical Data. | Int J Mol Sci | 2023 | 37833875 | PubTator, text mining | PubMed |
| Journey of CAR T‑cells: Emphasising the concepts and advancements in breast cancer (Review). | Int J Oncol | 2023 | 37830150 | PubTator, text mining | PubMed |
| [Antibody drug conjugates (ADC) and bispecific antibodies in oncology - report of the 2022 Saint Louis day]. | Bull Cancer | 2023 | 37827964 | PubTator, text mining | PubMed |
| A HER2-targeted Antibody-Drug Conjugate, RC48-ADC, Exerted Promising Antitumor Efficacy and Safety with Intravesical Instillation in Preclinical Models of Bladder Cancer. | Adv Sci (Weinh) | 2023 | 37824205 | PubTator, text mining | PubMed |
| Next-generation antibody-drug conjugates revolutionize the precise classification and treatment of HER2-expressing breast cancer. | Cancer Biol Med | 2023 | 37823691 | PubTator, text mining | PubMed |
| The Therapeutic Effects of MUC1-C shRNA@Fe3O4 Magnetic Nanoparticles in Alternating Magnetic Fields on Triple-Negative Breast Cancer. | Int J Nanomedicine | 2023 | 37822991 | PubTator, text mining | PubMed |
| The Evolving Landscape of Antibody-Drug Conjugates: In Depth Analysis of Recent Research Progress. | Bioconjug Chem | 2023 | 37821099 | PubTator, text mining | PubMed |
| Recent Developments in the Therapeutic Landscape of Advanced or Metastatic Hormone Receptor-Positive Breast Cancer. | Cancer Res Treat | 2023 | 37817306 | PubTator, text mining | PubMed |
| The ATF2/miR-3913-5p/CREB5 axis is involved in the cell proliferation and metastasis of colorectal cancer. | Commun Biol | 2023 | 37816820 | PubTator, text mining | PubMed |
| Hypoxanthine guanine phosphoribosyltransferase 1, a target of miR-125b-5p, promotes cell proliferation and invasion in head and neck squamous cell carcinoma. | Heliyon | 2023 | 37810145 | PubTator, text mining | PubMed |
| Lymph Node Dissection in Upper Tract Urothelial Carcinoma: Current Status and Future Perspectives. | Curr Oncol Rep | 2023 | 37801187 | PubTator, text mining | PubMed |
| Managing adverse events of sacituzumab govitecan. | Expert Opin Biol Ther | 2023 | 37800595 | PubTator, text mining | PubMed |
| Antibody-drug conjugates: Recent advances in payloads. | Acta Pharm Sin B | 2023 | 37799390 | PubTator, text mining | PubMed |
| ACAA2 is a novel molecular indicator for cancers with neuroendocrine phenotype. | Br J Cancer | 2023 | 37798372 | PubTator, text mining | PubMed |
| Current management and future challenges in salivary glands cancer. | Front Oncol | 2023 | 37795454 | PubTator, text mining | PubMed |
| A comprehensive overview on antibody-drug conjugates: from the conceptualization to cancer therapy. | Front Pharmacol | 2023 | 37790810 | PubTator, text mining | PubMed |
Safety and effectiveness of sacituzumab govitecan in patients with metastatic triple-negative breast cancer in real-world settings: first observations from an interdisciplinary breast cancer centre in Germany. | Ther Adv Med Oncol | 2023 | 37789989 | PubTator, text mining | PubMed |
| Enfortumab vedotin in metastatic urothelial carcinoma: the solution EVentually? | Front Oncol | 2023 | 37781180 | PubTator, text mining | PubMed |
gene-search-2026-11-11-0.2.0
Sources 12
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- EMBL-EBI's patent proteinsNo added restrictions. Attribution expected
- GenBank's patent filesNo restrictions from NCBI. Submitters may hold rights
- HGNCCC0
- NCBI GenePublic domain (US government)
- NIH's project files and grant-paper linksPublic domain
- Open TargetsCC0 1.0
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- EMBL-EBI's patent proteinsEMBL-EBI's patent protein files from the EPO, JPO, KIPO and USPTO. EMBL-EBI: "EMBL-EBI itself places no additional restrictions on the use or redistribution of the data available via its Data Resources and Tools other than those provided by the original data owners" and "EMBL-EBI expects attribution (e.g. in publications, services or products) for the use of any of its Data Resources and Tools." Read on 11 Nov 2026 at https://www.ebi.ac.uk/about/terms-of-use
- GenBank's patent filesGenBank's patent files. NCBI: "NCBI places no restrictions on the use or distribution of the GenBank data. However, some submitters may claim patent, copyright, or other intellectual property rights in all or a portion of the data they have submitted." Read on 11 Nov 2026 at https://www.ncbi.nlm.nih.gov/genbank/about/
- HGNCCC0: https://www.genenames.org/about/license/
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH's project files and grant-paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/genes/v1/4070/papers?page=48